Abstract
Aim
A new method of assessing the coefficient of failure of pancreatic β-cells from any
index of glycaemia has been proposed. This method of analysis has been used to assess
data on HbA1c and fasting glucose concentrations from a randomised study comparing
pioglitazone with acarbose.
Methods
Patients were treated for 26 weeks with either pioglitazone 45 mg once daily or acarbose
300 mg/day as 3 equal doses. Plasma HbA1c concentration was measured every two months
and fasting glucose was measured monthly. The coefficient of failure was determined
for each patient from the slope of the least squares regression line over time.
Results
The coefficient of failure from HbA1c was - 2.65 ± 2.13 %/year with pioglitazone and
- 1.25 ± 3.11 %/year with acarbose, indicating improved β-cell function in each case.
The coefficient of failure was improved to a significantly greater extent with pioglitazone
(P < 0.001). Coefficient of failure from fasting blood glucose also showed a greater
improvement with pioglitazone (- 53.1 ± 95.0 mg/dl/year) than with acarbose (- 29.9
± 142.5 mg/dl/year; p = 0.049).
Conclusion
The coefficient of failure showed a significantly greater improvement of β-cell function
with pioglitazone than with acarbose during 26 weeks of treatment.
Key words
Beta-cell function - coefficient of failure - pioglitazone - acarbose
References
- 1
Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R.
Assessment of insulin sensitivity and beta-cell function from measurements in the
fasting state and during an oral glucose tolerance test.
Diabetologia.
2000;
43
1507-1511
- 2
Buchanan T A, Xiang A H, Peters R K, Kjos S L, Marroquin A, Goico J, Ochoa C, Tan S,
Berkowitz K, Hodis H N, Azen S P.
Preservation of Pancreatic β-cell function and prevention of type 2 diabetes by pharmacological
treatment of insulin resistance in high-risk Hispanic women.
Diabetes.
2002;
51
2796-2803
- 3
Desvergne B, Wahli W.
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
Endocr Rev.
1999;
20
649-688
- 4
Göke B. on behalf of the German Pioglitazone Study Group .
Improved glycaemic control and lipid profile in a randomised study of pioglitazone
compared with acarbose in patients with type 2 diabetes mellitus.
Treatments Endocrinol.
2002;
1
329-336
- 5
Holman R R, Cull C A, Turner R C.
A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycaemic
control over 3 years (UKPDS 44).
Diabetes Care.
1999;
22
960-964
- 6
Otto C, Lehke M, Göke B.
Novel insulin sensitizers: pharmacogenomic aspects.
Pharmacogenomics.
2002;
3
1-18
- 7
Ovalle F, Bell D SH.
Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function
in patients with type 2 diabetes mellitus.
Diabetes Obes Metab.
2002;
4
56-59
- 8
Rosenstock J.
Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis
of pioglitazone therapy.
Diabetologia.
2000;
43(Suppl 1)
A192
- 9
Turner R C, Cull C A, Frighi V, Holman R R.
Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with
type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
J Am Med Assoc.
1999;
281
2005-2012
- 10
Group U KPDS.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998 a;
352
837-854
- 11
Group U KPDS.
UK Prospective Diabetes Study 26: Sulphonylurea failure in non-insulin dependent diabetic
patients over 6 years.
Diabet Med.
1998 b;
15
297-303
- 12
Wallace T M, Matthews D R.
The assessment of insulin resistance in man.
Diabet Med.
2002 a;
19
527-534
- 13
Wallace T M, Matthews D R.
Coefficient of failure: a methodology for examining longitudinal β-cell function in
type 2 diabetes.
Diabet Med.
2002 b;
19
465-469
- 14
Weyer C, Bogardus C, Mott D M, Pratley R E.
The natural history of insulin secretory dysfunction and insulin resistance in the
pathogenesis of type 2 diabetes mellitus.
J Clin Invest.
1999;
104
787-794
Prof. Dr. med. B. Göke
Medizinische Klinik und Poliklinik II
University of Munich
Marchioninistraße 15
81377 München
Germany
Telefon: + 498970952390
Fax: + 49 89 70 95 88 87
eMail: bgoeke@med2.med.uni-muenchen.de
